Loading
A phase 2 trial of sintilimab in colorectal cancer, run by Yanhong Deng, now recruiting.
Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer is a phase 2, interventional study registered as NCT05450029 by Yanhong Deng, with a registry enrolment figure of 51 participants, started 2022-01-01 and due to reach its primary completion in 2024-01-01. Interventions recorded: Sintilimab. Conditions listed: Rectal Cancer. Primary outcome: Pathological complete response. Colorectal eligibility wording from the registry: "Treatment-naive patients with histological or cytological documentation of rectal adenocarcinoma (\<12 cm from the anal verge)". Sites: China. No results are recorded here; the registry entry is the source.
Shares Sintilimab, IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Sintilimab, IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Sintilimab, IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Sintilimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Sintilimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Sintilimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Sintilimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.